SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.580-3.0%Oct 28 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: End2War who wrote (1167)9/16/2025 1:06:09 PM
From: End2War3 Recommendations

Recommended By
bobbseytwins2001
erippetoe
Olecranon

   of 1216
 

Dr. Pat Soon-Shiong




@DrPatSoonShiong

·
23h

To be clear these patients with complete responses in Waldenstrom did not undergo the standard of care lymphodepletion..,meaning the trial we are running is entirely chemo free
@cssifm
. The patients are receiving our targeted NK cell therapy and Anktiva plus a targeted Antibody
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News